WO2022152204A1 - 一种人***瘤病毒病毒样颗粒疫苗的稳定制剂 - Google Patents
一种人***瘤病毒病毒样颗粒疫苗的稳定制剂 Download PDFInfo
- Publication number
- WO2022152204A1 WO2022152204A1 PCT/CN2022/071782 CN2022071782W WO2022152204A1 WO 2022152204 A1 WO2022152204 A1 WO 2022152204A1 CN 2022071782 W CN2022071782 W CN 2022071782W WO 2022152204 A1 WO2022152204 A1 WO 2022152204A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- hpv
- type
- protein
- fragment
- Prior art date
Links
- 241000701806 Human papillomavirus Species 0.000 title claims abstract description 94
- 238000002360 preparation method Methods 0.000 title claims abstract description 67
- 108010042365 Virus-Like Particle Vaccines Proteins 0.000 title claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 87
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 84
- 239000002245 particle Substances 0.000 claims abstract description 62
- 239000002671 adjuvant Substances 0.000 claims abstract description 43
- 229960005486 vaccine Drugs 0.000 claims abstract description 19
- 230000003204 osmotic effect Effects 0.000 claims abstract description 13
- 239000004094 surface-active agent Substances 0.000 claims abstract description 12
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910052782 aluminium Inorganic materials 0.000 claims abstract description 8
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 8
- 241001631646 Papillomaviridae Species 0.000 claims description 69
- 239000000203 mixture Substances 0.000 claims description 58
- 238000009472 formulation Methods 0.000 claims description 51
- 150000001413 amino acids Chemical class 0.000 claims description 48
- 239000012634 fragment Substances 0.000 claims description 44
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 34
- 210000004898 n-terminal fragment Anatomy 0.000 claims description 32
- 210000004899 c-terminal region Anatomy 0.000 claims description 27
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 25
- 239000000872 buffer Substances 0.000 claims description 24
- 239000011780 sodium chloride Substances 0.000 claims description 17
- 210000004900 c-terminal fragment Anatomy 0.000 claims description 16
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 16
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 16
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 16
- 229940068968 polysorbate 80 Drugs 0.000 claims description 16
- 229920000053 polysorbate 80 Polymers 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 229940047712 aluminum hydroxyphosphate Drugs 0.000 claims description 8
- 230000005847 immunogenicity Effects 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 229910017119 AlPO Inorganic materials 0.000 claims description 6
- 229960002566 papillomavirus vaccine Drugs 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 101000781698 Human papillomavirus 35 Major capsid protein L1 Proteins 0.000 claims description 2
- 241000701828 Human papillomavirus type 11 Species 0.000 claims description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 2
- 239000008351 acetate buffer Substances 0.000 claims description 2
- 238000007792 addition Methods 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- 230000030648 nucleus localization Effects 0.000 claims description 2
- 208000003154 papilloma Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 2
- 235000011152 sodium sulphate Nutrition 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 230000001568 sexual effect Effects 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 description 54
- 102000036639 antigens Human genes 0.000 description 53
- 108091007433 antigens Proteins 0.000 description 53
- 238000001179 sorption measurement Methods 0.000 description 35
- 238000012360 testing method Methods 0.000 description 33
- 238000004458 analytical method Methods 0.000 description 28
- 238000001514 detection method Methods 0.000 description 25
- 239000013641 positive control Substances 0.000 description 17
- 238000002965 ELISA Methods 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 13
- 230000003472 neutralizing effect Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 229940124866 human papillomavirus vaccine Drugs 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000007790 solid phase Substances 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 206010008342 Cervix carcinoma Diseases 0.000 description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 5
- 201000010881 cervical cancer Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- 238000012417 linear regression Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 231100000315 carcinogenic Toxicity 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010059313 Anogenital warts Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229940124897 Gardasil Drugs 0.000 description 2
- 241000341655 Human papillomavirus type 16 Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 208000009608 Papillomavirus Infections Diseases 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 206010061978 Genital lesion Diseases 0.000 description 1
- 101710121996 Hexon protein p72 Proteins 0.000 description 1
- 101100209954 Human papillomavirus type 16 L1 gene Proteins 0.000 description 1
- 108700025391 Human papillomavirus type 6 L1 Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 101710135729 Major capsid protein L1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710157639 Minor capsid protein Proteins 0.000 description 1
- 101710163801 Minor capsid protein L2 Proteins 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710136297 Protein VP2 Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the invention relates to the field of biological medicine preparations, in particular to a stable human papilloma virus virus-like particle vaccine preparation.
- Cervical cancer is one of the most common female malignancies, with about 500,000 new patients worldwide every year, and the incidence rate ranks second among female tumors. More than 95% of cervical cancers are closely related to human papillomavirus (HPV) infection. In addition to directly causing cervical cancer, HPV is also significantly associated with bronchial, rectal, oral and skin cancers. In addition, HPV is the main pathogenic factor that causes skin and mucosal warts.
- HPV can be divided into high-risk, suspected carcinogenic and low-risk.
- High-risk and suspected carcinogenic types can induce cervical cancer and other cancers;
- high-risk types include 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59;
- suspected carcinogenic types include 26, 53, 66 , 68, 73, 82 types.
- Low-risk types are mostly related to genital warts, condyloma acuminatum and other diseases, including types 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and 89.
- HPV6, 11, and 16 are the subtypes with the highest detection rate in patients with genital lesions.
- HPV vaccine is an effective way to block papillomavirus infection.
- Virus-like particle (VLP) vaccine is the most advantageous form of vaccine.
- VLP-based HPV vaccines are type-restricted, that is, they only have a strong protective effect on HPV of the same type of VLPs in the vaccine.
- the development of a multivalent HPV vaccine is necessary to provide broad protection.
- human papillomavirus vaccine formulations undergo a storage and transport process during which the antigen undergoes physical and chemical degradation. These instabilities may reduce the immunogenicity and/or safety of the antigen, so A stable formulation is needed to ensure that the antigen remains immunogenic and safe for prophylaxis prior to administration.
- the present invention provides a stable formulation of a multivalent human papillomavirus virus-like particle vaccine for preventing HPV-related disease or infection, comprising a plurality of papillomavirus virus-like particles, which are adsorbed on an adjuvant; physiologically Acceptable concentrations of buffers, osmotic pressure regulators, and optionally surfactants.
- human papillomavirus virus-like particles are selected from HPV types 6, 11, 16, 18, 31, 33, 45
- HPV virus-like particles assembled from the L1 protein of types 52 and 58;
- HPV virus-like particles assembled from L1 proteins of other pathogenic HPV types.
- Described buffer is selected from one or more of citrate buffer, acetate buffer or histidine buffer;
- Described osmotic pressure regulator is selected from one or more of sodium chloride, sodium phosphate or sodium sulfate;
- the surfactant is polyethoxy ether, preferably polysorbate 80;
- the adjuvant is selected from one or more of aluminum hydroxyphosphate (AlPO 4 ), amorphous aluminum hydroxyphosphate sulfate (AAHS) or aluminum hydroxide (Al(OH 3 )), preferably aluminum hydroxyphosphate (AlPO 4 ).
- the concentration of the buffer is 10 mM to 26 mM, preferably 10 mM, 18 mM or 26 mM;
- the concentration of the osmotic pressure regulator is 150mM ⁇ 320mM, preferably 150mM or 320mM;
- the concentration of the surfactant is 0-0.02% by weight,
- the adjuvant has a concentration of about 1.0 mg/mL
- the pH of the formulation is 5.9-6.5, preferably 5.9, 6.2 or 6.5.
- the concentration of any type of papillomavirus virus-like particle comprising the polyvalent papillomavirus virus-like particle is 40 ⁇ g/mL to 120 ⁇ g/mL.
- the formulation contains a total of 0.74 mg/mL papillomavirus virus-like particles, 1.0 mg/mL aluminum phosphate adjuvant, 18 mM histidine buffer, 320 mM sodium chloride, and the pH of the formulation solution is 6.2 ;
- polysorbate 80 at a concentration not higher than 0.3 mg/mL.
- the one or more other pathogenic HPV types are selected from HPV types 35, 39, 51, 56 and 59.
- the HPV virus-like particles is a chimeric HPV virus-like particle comprising a chimeric HPV L1 protein; the chimeric HPV L1 protein From its N-terminal to C-terminal direction it includes:
- a Derived from an N-terminal fragment of the L1 protein of a first type of papillomavirus that retains the immunogenicity of the L1 protein of the first type, wherein the first type of papillomavirus is selected from HPV types 6, 11 HPV types 16, 18, 31, 33, 45, 52 and 58 and one or more other pathogenic HPV types; and
- the second type of papillomavirus L1 protein has the characteristics of better expression and solubility than other types of L1 protein;
- the chimeric HPV L1 protein has the immunogenicity of the first type of papillomavirus L1 protein.
- the N-terminal fragment is a fragment obtained by truncating the C-terminal of the native sequence of the first type papillomavirus L1 protein to any amino acid site in its ⁇ 5 region, and the same A fragment having at least 98% identity; and the C-terminal fragment is obtained by truncating the N-terminus of the native sequence of the L1 protein of type 2 papillomavirus to any amino acid site within its ⁇ 5 region fragments, as well as functional variants resulting from further mutations, deletions and/or additions to the fragments.
- the C-terminal fragment contains one or more nuclear localization sequences.
- the first type of papilloma L1 protein is selected from the group consisting of HPV types 6, 11, 16, 18, 31, 35, 39, 45, 51, 52, Type 56 or Type 58; preferably, its native sequence is SEQ ID No:30, SEQ ID No:31, SEQ ID No:32, SEQ ID No:33, SEQ ID No:34, SEQ ID No:35, respectively, SEQ ID No:36, SEQ ID No:37, SEQ ID No:38, SEQ ID No:39, SEQ ID No:40, or the amino acid sequence encoded by the coding gene shown in SEQ ID No:41;
- the second type of papillomavirus L1 protein is selected from HPV type 16, type 28, type 33, type 59, or type 68 L1 protein;
- the second type of papillomavirus L1 protein is selected from HPV type 33 or HPV type 59 L1 protein.
- the C-terminal fragment is SEQ ID No: 1; or a fragment with a length of m1 amino acids, preferably a fragment covering amino acids 1-m1 of SEQ ID No: 1; wherein m1 is 8- An integer of 26; or the C-terminal fragment is SEQ ID No: 2; or a fragment of m2 amino acids in length, preferably a fragment covering amino acids 1-m2 of SEQ ID No: 2; wherein m2 is 13-31 the integer.
- the C-terminal fragment is SEQ ID No: 3; or a fragment having a length of n amino acids, preferably a fragment covering amino acids 1-n of SEQ ID No: 3; wherein n is 16- An integer of 38.
- the N-terminal fragment of the HPV type 6 L1 protein has 98% of the fragment obtained by truncating the C-terminal of the sequence shown in SEQ ID No: 4 at any amino acid site in its ⁇ 5 region , 98.5%, 99%, 99.5%, 99% or 100% identity;
- N-terminal fragment of the HPV 11 type L1 protein and the fragment obtained by truncating the C-terminal of the sequence shown in SEQ ID No: 5 to any amino acid site in its ⁇ 5 region have 98%, 98.5%, 99% , 99.5%, 99% or 100% identity;
- N-terminal fragment of the HPV 16 type L1 protein and the fragment obtained by truncating the C-terminal of the sequence shown in SEQ ID No: 6 to any amino acid site in its ⁇ 5 region have 98%, 98.5%, 99% , 99.5%, 99% or 100% identity;
- N-terminal fragment of the HPV 18 type L1 protein and the fragment obtained by truncating the C-terminal of the sequence shown in SEQ ID No: 7 to any amino acid site in its ⁇ 5 region have 98%, 98.5%, 99% , 99.5%, 99% or 100% identity;
- N-terminal fragment of the HPV 31 type L1 protein and the fragment obtained by truncating the C-terminal of the sequence shown in SEQ ID No: 8 to any amino acid site in its ⁇ 5 region have 98%, 98.5%, 99% , 99.5%, 99% or 100% identity;
- N-terminal fragment of the HPV 35 L1 protein and the fragment obtained by truncating the C-terminal of the sequence shown in SEQ ID No: 9 to any amino acid site in its ⁇ 5 region have 98%, 98.5%, 99% , 99.5%, 99% or 100% identity;
- N-terminal fragment of the HPV 39 type L1 protein and the fragment obtained by truncating the C-terminal of the sequence shown in SEQ ID No: 10 to any amino acid site in its ⁇ 5 region have 98%, 98.5%, 99% , 99.5%, 99% or 100% identity;
- N-terminal fragment of the HPV 45 type L1 protein and the fragment obtained by truncating the C-terminal of the sequence shown in SEQ ID No: 11 to any amino acid site in its ⁇ 5 region have 98%, 98.5%, 99% , 99.5%, 99% or 100% identity;
- N-terminal fragment of the HPV 51 type L1 protein and the fragment obtained by truncating the C-terminal of the sequence shown in SEQ ID No: 12 to any amino acid site in its ⁇ 5 region have 98%, 98.5%, 99% , 99.5%, 99% or 100% identity;
- N-terminal fragment of the HPV 52 type L1 protein and the fragment obtained by truncating the C-terminal of the sequence shown in SEQ ID No: 13 to any amino acid site in its ⁇ 5 region have 98%, 98.5%, 99% , 99.5%, 99% or 100% identity;
- N-terminal fragment of the HPV 56 type L1 protein and the fragment obtained by truncating the C-terminal of the sequence shown in SEQ ID No: 14 to any amino acid site in its ⁇ 5 region have 98%, 98.5%, 99% , 99.5%, 99% or 100% identity;
- N-terminal fragment of the HPV 58 type L1 protein and the fragment obtained by truncating the C-terminal of the sequence shown in SEQ ID No: 15 to any amino acid site in its ⁇ 5 region have 98%, 98.5%, 99% , 99.5%, 99% or 100% identity.
- the C-terminus of the N-terminal fragment is linked directly or via a linker to the N-terminus of the C-terminal fragment.
- the following contiguous amino acid sequence exists within the range of plus or minus 4 amino acid positions of the junction point: RKFL; preferably Typically, the following contiguous amino acid sequence exists within plus or minus 6 amino acid positions of the junction: LGRKFL.
- the chimeric HPV types 6, 11, 16, 18, 31, 35, 39, 45, 51, 52, 56 and 58 chimeric HPV The L1 protein is associated with SEQ ID No: 16, SEQ ID No: 17, SEQ ID No: 18, SEQ ID No: 19, SEQ ID No: 20, SEQ ID No: 21, SEQ ID No: 22, SEQ ID No: 19, SEQ ID No: 21, SEQ ID No: 22, SEQ ID No: 23.
- SEQ ID No: 24, SEQ ID No: 25, SEQ ID No: 26 and SEQ ID No: 27 are 98%, 98.5%, 99%, 99.5% or 100% identical; and HPV type 33 L1 protein and HPV59 type L1 proteins are 98%, 98.5%, 99%, 99.5% or 100% identical to SEQ ID No: 28 and SEQ ID No: 29, respectively.
- the formulation comprises SEQ ID No: 16, SEQ ID No: 17, SEQ ID No: 18, SEQ ID No: 19, SEQ ID No: 20, SEQ ID No: 21, SEQ ID No: 18, SEQ ID No: 19, SEQ ID No: 20, SEQ ID No: 21, respectively.
- the present invention provides a method of preventing HPV-related disease or infection, comprising: administering to a subject a stable formulation of the multivalent human papillomavirus virus-like particle vaccine formulation.
- the prevention can be thought of as treatment, and the two are used interchangeably.
- the subject is a human.
- the formulation is stable for at least 24 months at 2-8°C and at least 16 weeks at 25°C.
- the present invention provides use of the human papillomavirus virus-like particle vaccine formulation in the preparation of a vaccine for preventing HPV-related disease or infection.
- Fig. 1 is the adsorption degree detection result of each formula sample in Example 1.
- Fig. 2 is the antigen content analysis result of each formula sample in Example 1.
- T0 37°C, week 0; 37°C_1W: 37°C, week 1; 37°C_2W: 37°C, week 2; 37°C_4W: 37°C, week 4.
- Fig. 3 is the adsorption degree detection result of each formula sample in Example 2.
- Fig. 4 is the antigen content analysis result of each formula sample in Example 2.
- T0 37°C, week 0; 37°C_1W: 37°C, week 1; 37°C_2W: 37°C, week 2; 37°C_4W: 37°C, week 4.
- Fig. 5 is the adsorption degree detection result of each formula sample in Example 3.
- Fig. 6 is the antigen content analysis result of each formula sample in Example 3.
- T0 37°C, week 0; 37°C_1W: 37°C, week 1; 37°C_2W: 37°C, week 2; 37°C_4W: 37°C, week 4.
- Fig. 7 is the adsorption degree detection result of each formula sample in Example 4.
- FIG. 8 is the analysis result of antigen content of each formula sample in Example 4.
- T0 37°C, week 0; 37°C_1W: 37°C, week 1; 37°C_2W: 37°C, week 2; 37°C_4W: 37°C, week 4.
- the invention provides a stable preparation of human papillomavirus vaccine, which solves the problem of antibody stability during storage and transportation. Ensure that the pre-administration antigen still has the immunogenicity and safety required for prophylaxis.
- formulation refers to a composition that maintains the biological activity of the active ingredient effective and that is free of other ingredients that would be unacceptably toxic to the subject. Such formulations are sterile. "Aseptic” refers to the absence of viable bacteria or the absence or substantial absence of all viable microorganisms and their spores.
- a “stable” formulation refers to a formulation in which the active ingredient substantially retains its physical and/or chemical stability and/or biological activity upon storage.
- the formulation substantially retains its physical and chemical stability, as well as its biological activity, upon storage.
- patient or “subject” are used interchangeably and refer to any mammal suffering from a condition or disease according to the present invention. People are preferred.
- physiologically acceptable refers to a buffer, excipient, or salt at a concentration or ionic strength that renders the formulation biologically compatible with the target host, eg, a human, to be immunized.
- the stable formulation of the present invention contains human papillomavirus virus-like particles, a buffer, an osmotic pressure regulator and an aluminum adjuvant.
- buffer refers to a buffered solution that resists changes in pH through the action of its acid-base complexing components.
- a histidine buffer is selected, and the pH of the formulation solution is preferably about 5.9-6.5, more preferably 6.2.
- surfactant refers to a surfactant, in one embodiment, the surfactant herein is polysorbate 80.
- osmotic pressure regulator means a pharmaceutically acceptable osmotic pressure regulator. Suitable osmotic pressure regulators include, but are not limited to, salts, in one embodiment of the invention sodium chloride (NaCl) at a concentration of about 150 mM to 320 mM.
- NaCl sodium chloride
- adjuvant refers to a compound or mixture that enhances an immune response.
- vaccines may contain adjuvants.
- the adjuvant used in the present invention is selected from one or more of aluminum hydroxyphosphate (AlPO 4 ), amorphous aluminum hydroxyphosphate sulfate (AAHS) or aluminum hydroxide (Al(OH 3 )), preferably a hydroxyl group Aluminum Phosphate (AlPO 4 ).
- the "stability" of a protein after storage at a selected temperature for a selected period of time can be qualitatively and/or quantitatively assessed in a number of different ways.
- the content of active antigen that can bind to the neutralizing antibody of recombinant human papilloma virus is obtained by enzyme-linked immunosorbent assay (ELISA), the ratio of the content of active antigen to T 0 at each time point is compared, and the content of each preparation is compared.
- the antigens not adsorbed to the aluminum phosphate adjuvant were obtained by centrifugation, and the content was analyzed, and the adsorption degree was calculated;
- the EC50 of recombinant human papillomavirus neutralizing antibodies was calculated as the ratio of the EC50 of the vaccine formulation to the positive control to determine the relative potency of the vaccine in vitro.
- immunogenicity refers to the ability of a substance, such as a protein or polypeptide, to stimulate an immune response, ie to stimulate the production of antibodies, especially humoral or cell-mediated responses.
- HPV or "HPV virus” refers to papillomaviruses of the family Papillomaviridae, which are non-enveloped DNA viruses whose genome is a double-stranded, closed-circle DNA of approximately 8 kb in size and can generally be divided into three regions: 1Early region (E), contains 6 open reading frames encoding E1, E2, E4-E7 viral replication, transcription and transformation-related non-structural proteins, as well as E3 and E8 open reading frames; 2Late region (L) contains coding The reading frames of the major capsid protein L1 and the minor capsid protein L2; 3 The long regulatory region (LCR) does not encode any protein, but has the origin of replication and multiple transcription factor binding sites.
- E E
- L contains 6 open reading frames encoding E1, E2, E4-E7 viral replication, transcription and transformation-related non-structural proteins, as well as E3 and E8 open reading frames
- 2Late region (L) contains coding The reading frames of the
- HPV L1 protein and HPV L2 protein refer to proteins encoded by the late region (L) of the HPV gene and synthesized late in the HPV infection cycle.
- the L1 protein is the major capsid protein and has a molecular weight of 55-60 kDa.
- the L2 protein is a minor capsid protein. Seventy-two L1 pentamers form the shell of the icosahedral HPV virion, wrapping the closed-loop double-stranded DNA minichromosome.
- the L2 protein is located inside the L1 protein.
- virus-like particle is a hollow particle containing one or more structural proteins of a virus, without viral nucleic acid.
- concentration of papillomavirus virus-like particles of any type refers to the amount of papillomavirus virus-like particles of any type in the formulation, while the term “total concentration of papillomavirus virus-like particles of all types” refers to the formulation The sum of the concentrations of the individual types of papillomavirus virus-like particles contained in .
- One embodiment of the present invention employs the human papillomavirus multivalent immunogenic composition described in the patent application PCT/CN2020/102601 filed on July 17, 2020, which is incorporated herein by reference and claims.
- the formulation contains 0.74 mg/mL papillomavirus virus-like particles, 1.0 mg/mL aluminum phosphate adjuvant, 18 mM histidine buffer, 320 mM sodium chloride, pH 6.2 .
- the vaccine will contain polysorbate 80 with a concentration of not higher than 0.3 mg/mL.
- the preparation has good stability, and can be stored stably for at least 24 months at 2-8° C. and at least 16 weeks at 25° C.
- the formulations of the present invention may be provided in liquid form or may be provided in lyophilized form.
- the lyophilized formulation can be reconstituted by prior administration.
- the detection method used is as follows:
- Positive control human papillomavirus virus-like particle standard, source: Shenzhou Cell Engineering Co., Ltd., chimeric HPV types 6, 16, 18, 31, 35, 30,
- the recombinant human papillomavirus neutralizing antibody (source: Beijing Yiqiao Shenzhou Technology Co., Ltd., the same below) is combined with a solid-phase carrier to form a solid-phase antibody.
- the recombinant human papillomavirus neutralizing antibody is combined with a solid phase carrier to form a solid phase antibody.
- the sample to be tested was centrifuged, and the supernatant was taken as the test sample.
- Adsorption degree (%) (1-antigen concentration in supernatant/antigen concentration of test sample)%.
- the positive control 14-valent human papillomavirus vaccine (types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) controls, Source: Beijing Shenzhou Cell Biotechnology Group Co., Ltd., the sequence is the same as the protein sequence in the test product) and the test product were completely dissolved, as the positive control and the test product to be tested.
- Dilute recombinant human papillomavirus neutralizing antibody to a final concentration of 2 ⁇ g/mL add 100 ⁇ L/well to a 96-well plate, tap the plate to mix the samples, and coat overnight at 4°C; use washing solution at 200 ⁇ L/well Wash the plate once and dry the ELISA plate; then block the ELISA plate with 300 ⁇ L/well of blocking solution for one hour at room temperature; wash twice with 300 ⁇ L/well of washing solution, add 100 ⁇ L of treated Blank control (corresponding buffer for the test product), positive control to be tested and test product, act for 1 hour at room temperature; after washing the plate 3 times with washing solution at 200 ⁇ L/well, add diluted enzyme at 100 ⁇ L/well Labeled recombinant human papillomavirus neutralizing antibody; act for 1 hour at room temperature, wash the plate three times with 200 ⁇ L/well of washing solution, add chromogenic solution at 200 ⁇ L/well, and leave at room temperature for 20 ⁇ 5min; stop
- the computer program Origin or the four-parameter fitting method is used for processing. Taking the concentration of the positive control or the test product as the abscissa, and the average absorbance intensity as the ordinate, the EC 50 of the test product and the positive control is obtained, and the EC 50 of the test product is obtained. 50 was divided by the EC 50 of the positive control to obtain the in vitro relative potency of the test article (M. Shank-Retzlaff, F. Wang, T. Morley et al. Correlation between Mouse Potency and In Vitro Relative Potency for Human Papillomavirus Type 16 Virus-Like Particles and Gardasil Vaccine Samples. Human Vaccines, 1:5, 191-197).
- Preparation formula number papillomavirus virus-like particle Aluminum phosphate adjuvant Histidine buffer Sodium chloride Polysorbate 80 pH F1 0.74mg/mL 1.0mg/mL 18mM 320mM 0.00wt% 6.5 F2 0.74mg/mL 1.0mg/mL 18mM 320mM 0.02wt% 6.5
- Adsorption degree analysis The detection principle is to obtain the antigen not adsorbed on the aluminum phosphate adjuvant by centrifugation and analyze the content to calculate the adsorption degree.
- Antigen content analysis The detection principle is to obtain the active antigen content that can be combined with recombinant human papillomavirus neutralizing antibody by ELISA, and compare the stability of each preparation by comparing the ratio of the active antigen content at each time point to T 0 . The higher the value, the higher the active antigen content in the preparation, and the better the activity is maintained.
- test results showed that the adsorption degrees of the two papillomavirus virus-like particle vaccine preparations were both above 99%, and there was no significant difference in the change trend of the antigen content of the papillomavirus virus-like particle vaccine in F1 and F2. Stability is comparable.
- Preparation formula number papillomavirus virus-like particle Aluminum phosphate adjuvant Histidine buffer Sodium chloride Polysorbate 80 pH F1 0.74mg/mL 1.0mg/mL 18mM 320mM 0.00wt% 5.9 F2 0.74mg/mL 1.0mg/mL 18mM 320mM 0.00wt% 6.2 F3 0.74mg/mL 1.0mg/mL 18mM 320mM 0.00wt% 6.5
- Adsorption degree analysis The detection principle is to obtain the antigens that are not adsorbed on the aluminum phosphate adjuvant by centrifugation, analyze the content, and calculate the adsorption degree.
- Antigen content analysis The detection principle is to obtain the active antigen content that can be combined with recombinant human papillomavirus neutralizing antibody by ELISA, and compare the stability of each preparation by comparing the ratio of the active antigen content at each time point to T 0 . The higher the value, the higher the active antigen content in the preparation, and the better the activity is maintained.
- the test results showed that the adsorption degrees of the three papillomavirus virus-like particle vaccine preparations were all above 99%, and the change trend of the antigen content of the papillomavirus virus-like particle vaccine in F1 and F2 was better than that in the F3 preparation, namely F1 and F2.
- the stability is better than F3.
- Example 3 Screening study of osmotic pressure regulator concentration
- Preparation formula number papillomavirus virus-like particle Aluminum phosphate adjuvant Histidine buffer Sodium chloride Polysorbate 80 pH F1 0.74mg/mL 1.0mg/mL 18mM 320mM 0.00wt% 6.2 F2 0.74mg/mL 1.0mg/mL 18mM 150mM 0.00wt% 6.2
- Adsorption degree analysis The detection principle is to obtain the antigens that are not adsorbed on the aluminum phosphate adjuvant by centrifugation, analyze the content, and calculate the adsorption degree.
- Antigen content analysis The detection principle is to obtain the active antigen content that can be combined with recombinant human papillomavirus neutralizing antibody by ELISA, and compare the stability of each preparation by comparing the ratio of the active antigen content at each time point to T 0 . The higher the value, the higher the active antigen content in the preparation, and the better the activity is maintained.
- test results showed that the adsorption degrees of the two papillomavirus virus-like particle vaccine preparations were both above 99%. At 37°C for 4 weeks, there was no significant difference in the changes of the active antigen content in the F1 and F2 preparations, that is, the stability of F1 and F2. Sexually quite.
- Preparation formula number papillomavirus virus-like particle Aluminum phosphate adjuvant Histidine buffer Sodium chloride Polysorbate 80 pH F1 0.74mg/mL 1.0mg/mL 10mM 320mM 0.00wt% 6.2 F2 0.74mg/mL 1.0mg/mL 18mM 320mM 0.00wt% 6.2 F3 0.74mg/mL 1.0mg/mL 26mM 320mM 0.00wt% 6.2
- Adsorption degree analysis The detection principle is to obtain the antigens that are not adsorbed on the aluminum phosphate adjuvant by centrifugation, analyze the content, and calculate the adsorption degree.
- Antigen content analysis The detection principle is to obtain the active antigen content that can be combined with recombinant human papillomavirus neutralizing antibody by ELISA, and compare the stability of each preparation by comparing the ratio of the active antigen content at each time point to T 0 . The higher the value, the higher the active antigen content in the preparation, and the better the activity is maintained.
- test results are shown in Table 11-12 and Figure 7-8.
- the test results showed that the adsorption degrees of the three papillomavirus virus-like particle vaccine preparations were all above 99%, and the change trend of the antigen content of the papillomavirus virus-like particle vaccine in F1 and F2 was better than that in the F3 preparation, namely F1 and F2.
- the stability is better than F3.
- Example 5 Prescription confirmation of various types (6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) papillomavirus virus-like particle vaccine formulations
- papillomavirus virus-like particle vaccine preparations (preparation formula is 0.74mg/mL) Papilloma virus virus-like particles + 1.0 mg/mL aluminum phosphate adjuvant + 18 mM histidine buffer + 320 mM sodium chloride, pH 6.2) to conduct a stability study at 2-8 °C, where due to the process in the preparation process Residual, the vaccine will contain polysorbate 80 at a concentration of no higher than 0.3 mg/mL.
- the investigation time points were 3m (3 months), 6m (6 months), 9m (9 months), and 12m (12 months), and the investigation items were adsorption degree and in vitro relative efficacy.
- Adsorption degree The detection principle is to obtain the antigen that is not adsorbed on the aluminum phosphate adjuvant by centrifugation and analyze the content to calculate the adsorption degree.
- Relative potency in vitro The detection principle of this method is to calculate the percentage of EC 50 of the test article and the positive control by detecting the EC 50 of the test article, the positive control and the recombinant human papillomavirus neutralizing antibody respectively. The higher the relative potency of the test article in vitro, the better the quality of the test article.
- the experimental results show that the various types of papillomavirus virus-like particle vaccine preparations disclosed in the present invention have good stability, and can be stored stably for at least 12 months at 2-8°C.
- Example 6 Preparation of 14-valent human papillomavirus vaccine (types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) preparation and prescription verification experiment
- Adsorption degree The detection principle is to obtain the antigen that is not adsorbed on the aluminum phosphate adjuvant by centrifugation and analyze the content to calculate the adsorption degree.
- Relative potency in vitro The detection principle of this method is to calculate the percentage of EC 50 of the test article and the positive control by detecting the EC 50 of the test article, the positive control and the recombinant human papillomavirus neutralizing antibody respectively. The higher the relative potency of the test article in vitro, the better the quality of the test article.
- the experimental results show that the fourteen-valent human papillomavirus vaccine (types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) formulations disclosed in the present invention have good Stability, stable storage for at least 24 months at 2-8 °C, and stable storage for at least 16 weeks at 25 °C.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
制剂配方编号 | ***瘤病毒病毒样颗粒 | 磷酸铝佐剂 | 组氨酸缓冲液 | 氯化钠 | 聚山梨酯80 | pH |
F1 | 0.74mg/mL | 1.0mg/mL | 18mM | 320mM | 0.00wt% | 6.5 |
F2 | 0.74mg/mL | 1.0mg/mL | 18mM | 320mM | 0.02wt% | 6.5 |
Num | 结合于铝佐剂的%HPV18 VLPs |
F1 | 99.8 |
F2 | 99.9 |
制剂配方编号 | ***瘤病毒病毒样颗粒 | 磷酸铝佐剂 | 组氨酸缓冲液 | 氯化钠 | 聚山梨酯80 | pH |
F1 | 0.74mg/mL | 1.0mg/mL | 18mM | 320mM | 0.00wt% | 5.9 |
F2 | 0.74mg/mL | 1.0mg/mL | 18mM | 320mM | 0.00wt% | 6.2 |
F3 | 0.74mg/mL | 1.0mg/mL | 18mM | 320mM | 0.00wt% | 6.5 |
Num | 结合于铝佐剂的%HPV18 VLPs |
F1 | 99.4 |
F2 | 99.4 |
F3 | 99.8 |
制剂配方编号 | ***瘤病毒病毒样颗粒 | 磷酸铝佐剂 | 组氨酸缓冲液 | 氯化钠 | 聚山梨酯80 | pH |
F1 | 0.74mg/mL | 1.0mg/mL | 18mM | 320mM | 0.00wt% | 6.2 |
F2 | 0.74mg/mL | 1.0mg/mL | 18mM | 150mM | 0.00wt% | 6.2 |
Num | 结合于铝佐剂的%HPV18 VLPs |
F1 | 99.4 |
F2 | 99.6 |
制剂配方编号 | ***瘤病毒病毒样颗粒 | 磷酸铝佐剂 | 组氨酸缓冲液 | 氯化钠 | 聚山梨酯80 | pH |
F1 | 0.74mg/mL | 1.0mg/mL | 10mM | 320mM | 0.00wt% | 6.2 |
F2 | 0.74mg/mL | 1.0mg/mL | 18mM | 320mM | 0.00wt% | 6.2 |
F3 | 0.74mg/mL | 1.0mg/mL | 26mM | 320mM | 0.00wt% | 6.2 |
Num | 结合于铝佐剂的%HPV18 VLPs |
F1 | 99.6 |
F2 | 99.4 |
F3 | 99.6 |
Claims (20)
- 一种预防HPV相关疾病或感染的多价人***瘤病毒病毒样颗粒疫苗的稳定制剂,含有(a)多种人***瘤病毒病毒样颗粒;(b)佐剂;(c)生理上可接受的浓度的缓冲液;(d)生理上可接受的浓度的渗透压调节剂;以及任选地(e)生理上可接受的浓度的表面活性剂,其中所述人***瘤病毒病毒样颗粒选自由HPV 6型、11型、16型、18型、31型、33型、45型、52型和58型的L1蛋白组装而成的HPV病毒样颗粒;和一种或多种由其他致病的HPV型别的L1蛋白组装而成的HPV病毒样颗粒,其中人***瘤病毒病毒样颗粒吸附在佐剂上。
- 根据权利要求1所述的制剂,其特征在于所述缓冲液选自柠檬酸缓冲液、醋酸缓冲液或组氨酸缓冲液的一种或多种;所述渗透压调节剂选自氯化钠、磷酸钠或硫酸钠的一种或多种;所述表面活性剂为多乙氧基醚,优选为聚山梨酯80;所述佐剂优选为铝佐剂,更优选为羟基磷酸铝(AlPO 4)、非晶形的羟基磷酸铝硫酸盐(AAHS)或氢氧化铝(Al(OH 3))的一种或多种,最优选为羟基磷酸铝(AlPO 4)。
- 根据权利要求1或2所述的制剂,其特征在于(a)所有型别的***瘤病毒病毒样颗粒的总计浓度为40~740μg/mL;(b)所述缓冲液的浓度为10mM~26mM,优选10mM、18mM或26mM;(c)所述渗透压调节剂的浓度为150mM~320mM,优选150mM或320mM;(d)所述表面活性剂的浓度为0~0.02wt%;(e)所述佐剂的浓度约为1.0mg/mL;(f)所述制剂的pH为5.9-6.5,优选5.9、6.2或6.5。
- 根据权利要求3所述的制剂,其特征在于组成所述多价***瘤病毒病毒样颗粒的任一型别***瘤病毒病毒样颗粒的浓度为40μg/mL~120μg/mL。
- 根据权利要求1-4之任一的制剂,其含有总计0.74mg/mL***瘤病毒病毒样颗粒,1.0mg/mL磷酸铝佐剂,18mM组氨酸缓冲液,320mM氯化钠,pH值为6.2;任选地,浓度不高于0.3mg/mL的聚山梨酯80。
- 根据权利要求5所述的制剂,其中所述一种或多种其他致病的HPV型别选自HPV 35 型、39型、51型、56型和59型。
- 根据权利要求6所述的制剂,其中至少一种所述HPV病毒样颗粒为嵌合的HPV病毒样颗粒,所述嵌合的HPV病毒样颗粒包含一种嵌合HPV L1蛋白;所述嵌合HPV L1蛋白自其N末端至C末端方向包含:a.衍生于第一型别***瘤病毒L1蛋白的N端片段,所述N端片段保持该型别L1蛋白的免疫原性,其中第一型别的***瘤病毒选自HPV 6型、11型、16型、18型、31型、33型、45型、52型和58型和一种或多种其他致病的HPV型别;和b.衍生于第二型别***瘤病毒L1蛋白的C端片段,所述第二型别***状瘤病毒L1蛋白具有相较于其他型别的L1蛋白表达量和可溶性较好的特性;其中嵌合HPV L1蛋白具有第一型别***瘤病毒L1蛋白的免疫原性。
- 根据权利要求7所述的制剂,其中所述N端片段为将所述第一型别***瘤病毒L1蛋白的天然序列的C端截短于其α5区内的任一氨基酸位点而得到的片段,以及与其具有至少98%的同一性的片段;并且所述C端片段为将第二型别***状瘤病毒L1蛋白的天然序列的N末端截短于其α5区内的任一氨基酸位点而得到的片段,以及该片段进一步突变、缺失和/或添加而产生的功能性变体。
- 根据权利要求8所述的制剂,其中所述C端片段含有一个或多个核定位序列。
- 根据权利要求7所述的制剂,其中所述第一型别***瘤L1蛋白选自HPV 6型、11型、16型、18型、31型、35型、39型、45型、51型、52型、56型或58型;优选地,其天然序列分别为为SEQ ID No:30,SEQ ID No:31,SEQ ID No:32,SEQ ID No:33,SEQ ID No:34,SEQ ID No:35,SEQ ID No:36,SEQ ID No:37,SEQ ID No:38,SEQ ID No:39,SEQ ID No:40,或SEQ ID No:41所示出的编码基因编码的氨基酸序列;其中所述第二型别***瘤病毒L1蛋白选自HPV 16型、28型、33型、59型或68型L1蛋白;更优选地,所述第二型别***瘤病毒L1蛋白选自HPV 33型或HPV 59型L1蛋白。
- 根据权利要求10所述的制剂,其中所述C端片段为SEQ ID No:1;或其长度为m1个氨基酸的片段,优选涵盖SEQ ID No:1的第1-m1位氨基酸的片段;其中m1为8-26的整数;或所述C端片段为SEQ ID No:2;或其长度为m2个氨基酸的片段,优选涵盖SEQ ID No:2的第1-m2位氨基酸的片段;其中m2为13-31的整数。
- 根据权利要求10所述的制剂,其中所述C端片段为SEQ ID No:3;或其长度为n个氨基酸的片段,优选涵盖SEQ ID No:3的第1-n位氨基酸的片段;其中n为16-38的整数。
- 根据权利要求7所述的制剂,其中所述HPV 6型L1蛋白的N端片段与将SEQ ID No:4所示序列的C末端截短于其α5区内的任一氨基酸位点而得到的片段具有98%、98.5%、99%、99.5%、99%或100%的同一性;所述HPV 11型L1蛋白的N端片段与将SEQ ID No:5所示序列的C末端截短于其α5区内的任一氨基酸位点而得到的片段具有98%、98.5%、99%、99.5%、99%或100%的同一性;所述HPV 16型L1蛋白的N端片段与将SEQ ID No:6所示序列的C末端截短于其α5区内的任一氨基酸位点而得到的片段具有98%、98.5%、99%、99.5%、99%或100%的同一性;所述HPV 18型L1蛋白的N端片段与将SEQ ID No:7所示序列的C末端截短于其α5区内的任一氨基酸位点而得到的片段具有98%、98.5%、99%、99.5%、99%或100%的同一性;所述HPV 31型L1蛋白的N端片段与将SEQ ID No:8所示序列的C末端截短于其α5区内的任一氨基酸位点而得到的片段具有98%、98.5%、99%、99.5%、99%或100%的同一性;所述HPV 35型L1蛋白的N端片段与将SEQ ID No:9所示序列的C末端截短于其α5区内的任一氨基酸位点而得到的片段具有98%、98.5%、99%、99.5%、99%或100%的同一性;所述HPV 39型L1蛋白的N端片段与将SEQ ID No:10所示序列的C末端截短于其α5区内的任一氨基酸位点而得到的片段具有98%、98.5%、99%、99.5%、99%或100%的同一性;所述HPV 45型L1蛋白的N端片段与将SEQ ID No:11所示序列的C末端截短于其α5区内的任一氨基酸位点而得到的片段具有98%、98.5%、99%、99.5%、99%或100%的同一性;所述HPV 51型L1蛋白的N端片段与将SEQ ID No:12所示序列的C末端截短于其α5区内的任一氨基酸位点而得到的片段具有98%、98.5%、99%、99.5%、99%或100%的同一性;所述HPV 52型L1蛋白的N端片段与将SEQ ID No:13所示序列的C末端截短于其α5区内的任一氨基酸位点而得到的片段具有98%、98.5%、99%、99.5%、99%或100%的同一性;所述HPV 56型L1蛋白的N端片段与将SEQ ID No:14所示序列的C末端截短于其α5区内的任一氨基酸位点而得到的片段具有98%、98.5%、99%、99.5%、99%或100%的同一性;和所述HPV 58型L1蛋白的N端片段与将SEQ ID No:15所示序列的C末端截短于其α5区内的任一氨基酸位点而得到的片段具有98%、98.5%、99%、99.5%、99%或100%的同一性。
- 根据权利要求7所述的制剂,所述N端片段的C末端与所述C端片段的N末端直接连接或通过接头连接。
- 根据权利要求7所述的制剂,其中当所述N端片段的C末端与所述C端片段的N末端连接时,在连接点的正负4个氨基酸位点的范围内存在以下连续氨基酸序列:RKFL;优选地,在连接点的正负6个氨基酸位点的范围内存在以下连续氨基酸序列:LGRKFL。
- 根据权利要求7所述的制剂,其中所述嵌合的HPV 6型、11型、16型、18型、31型、35型、39型、45型、51型、52型、56型和58型嵌合HPV L1蛋白分别与SEQ ID No:16、SEQ ID No:17、SEQ ID No:18、SEQ ID No:19、SEQ ID No:20、SEQ ID No:21、SEQ ID No:22、SEQ ID No:23、SEQ ID No:24、SEQ ID No:25、SEQ ID No:26和SEQ ID No:27具有98%、98.5%、99%、99.5%或100%的同一性;以及HPV 33型L1蛋白和HPV 59型L1蛋白分别与SEQ ID No:28和SEQ ID No:29具有98%、98.5%、99%、99.5%或100%的同一性。
- 根据权利要求16所述的制剂,其包含分别具有SEQ ID No:16、SEQ ID No:17、SEQ ID No:18、SEQ ID No:19、SEQ ID No:20、SEQ ID No:21、SEQ ID No:22、SEQ ID No:23、SEQ ID No:24、SEQ ID No:25、SEQ ID No:26和SEQ ID No:27所示氨基酸序列的HPV 6型、11型、16型、18型、31型、35型、39型、45型、51型、52型、56型和58型嵌合HPV L1蛋白;以及分别具有SEQ ID No:28和SEQ ID No:29所示氨基酸序列的HPV 33型L1蛋白和HPV 59型L1蛋白。
- 根据权利要求1-17所述的***瘤病毒疫苗的制剂,其特征在于,其在2~8℃条件下至少可稳定保存24个月,在25℃至少可稳定保存16个周。
- 一种预防HPV相关疾病或感染的方法,其包括:向受试者施用权利要求1-18中任一项所述的制剂。
- 权利要求1-18中任一项所述的制剂在制备一种用于预防HPV相关疾病或感染的疫苗中的应用。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280008056.4A CN117083078A (zh) | 2021-01-14 | 2022-01-13 | 一种人***瘤病毒病毒样颗粒疫苗的稳定制剂 |
CA3204802A CA3204802A1 (en) | 2021-01-14 | 2022-01-13 | Stable preparation of human papillomavirus virus-like particle vaccine |
US18/261,199 US20240075124A1 (en) | 2021-01-14 | 2022-01-13 | Stable formulation of human papillomavirus virus-like particle vaccine |
EP22739080.4A EP4292607A1 (en) | 2021-01-14 | 2022-01-13 | Stable preparation of human papillomavirus virus-like particle vaccine |
MX2023008306A MX2023008306A (es) | 2021-01-14 | 2022-01-13 | Preparacion estable de una vacuna con particulas similares al virus de papilomavirus humano. |
JP2023542604A JP2024503452A (ja) | 2021-01-14 | 2022-01-13 | ヒトパピローマウイルスウイルス様粒子ワクチンの安定な調製 |
KR1020237026965A KR20230129506A (ko) | 2021-01-14 | 2022-01-13 | 인간 유두종 바이러스 유사 입자 백신의 안정한 제제 |
AU2022207569A AU2022207569A1 (en) | 2021-01-14 | 2022-01-13 | Stable preparation of human papillomavirus virus-like particle vaccine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110049777.7 | 2021-01-14 | ||
CN202110049777 | 2021-01-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022152204A1 true WO2022152204A1 (zh) | 2022-07-21 |
Family
ID=82446926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/071782 WO2022152204A1 (zh) | 2021-01-14 | 2022-01-13 | 一种人***瘤病毒病毒样颗粒疫苗的稳定制剂 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20240075124A1 (zh) |
EP (1) | EP4292607A1 (zh) |
JP (1) | JP2024503452A (zh) |
KR (1) | KR20230129506A (zh) |
CN (1) | CN117083078A (zh) |
AU (1) | AU2022207569A1 (zh) |
CA (1) | CA3204802A1 (zh) |
MX (1) | MX2023008306A (zh) |
WO (1) | WO2022152204A1 (zh) |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001097840A1 (en) * | 2000-06-21 | 2001-12-27 | Medimmune, Inc. | Chimeric human papillomavirus (hpv) l1 molecules and uses therefor |
CN101245099A (zh) * | 2007-02-14 | 2008-08-20 | 马润林 | 重组人***瘤病毒l1衣壳蛋白的氨基酸序列及其应用 |
CN102349996A (zh) * | 2011-10-17 | 2012-02-15 | 沈阳三生制药有限责任公司 | 人***瘤病毒药物组合物及其应用 |
WO2021013078A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒52型l1蛋白 |
WO2021013060A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒51型l1蛋白 |
WO2021013076A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒45型l1蛋白 |
WO2021013075A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒18型l1蛋白 |
WO2021013073A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的***瘤病毒l1蛋白 |
WO2021013070A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒35型l1蛋白 |
WO2021013077A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒58型l1蛋白 |
WO2021013062A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒31型l1蛋白 |
WO2021013072A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒39型l1蛋白 |
WO2021013069A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒11型l1蛋白 |
WO2021013067A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒6型l1蛋白 |
WO2021013071A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 人***瘤病毒多价免疫原性组合物 |
WO2021013063A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒16型l1蛋白 |
WO2021013079A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒56型l1蛋白 |
-
2022
- 2022-01-13 JP JP2023542604A patent/JP2024503452A/ja active Pending
- 2022-01-13 WO PCT/CN2022/071782 patent/WO2022152204A1/zh active Application Filing
- 2022-01-13 MX MX2023008306A patent/MX2023008306A/es unknown
- 2022-01-13 US US18/261,199 patent/US20240075124A1/en active Pending
- 2022-01-13 EP EP22739080.4A patent/EP4292607A1/en active Pending
- 2022-01-13 KR KR1020237026965A patent/KR20230129506A/ko active Search and Examination
- 2022-01-13 CA CA3204802A patent/CA3204802A1/en active Pending
- 2022-01-13 CN CN202280008056.4A patent/CN117083078A/zh active Pending
- 2022-01-13 AU AU2022207569A patent/AU2022207569A1/en active Pending
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001097840A1 (en) * | 2000-06-21 | 2001-12-27 | Medimmune, Inc. | Chimeric human papillomavirus (hpv) l1 molecules and uses therefor |
CN101245099A (zh) * | 2007-02-14 | 2008-08-20 | 马润林 | 重组人***瘤病毒l1衣壳蛋白的氨基酸序列及其应用 |
CN102349996A (zh) * | 2011-10-17 | 2012-02-15 | 沈阳三生制药有限责任公司 | 人***瘤病毒药物组合物及其应用 |
WO2021013078A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒52型l1蛋白 |
WO2021013060A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒51型l1蛋白 |
WO2021013076A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒45型l1蛋白 |
WO2021013075A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒18型l1蛋白 |
WO2021013073A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的***瘤病毒l1蛋白 |
WO2021013070A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒35型l1蛋白 |
WO2021013077A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒58型l1蛋白 |
WO2021013062A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒31型l1蛋白 |
WO2021013072A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒39型l1蛋白 |
WO2021013069A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒11型l1蛋白 |
WO2021013067A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒6型l1蛋白 |
WO2021013071A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 人***瘤病毒多价免疫原性组合物 |
WO2021013063A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒16型l1蛋白 |
WO2021013079A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人***瘤病毒56型l1蛋白 |
Non-Patent Citations (6)
Title |
---|
CHRISTENSEN, N. D. ET AL.: "Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.", VIROLOGY., vol. 291, no. 2, 20 December 2001 (2001-12-20), XP002280750, DOI: 10.1006/viro.2001.1220 * |
JIN SHI: "Controlled Assembly of Human Papillomavirus Capsid Protein L1in Vitro", CHINESE DOCTORAL DISSERTATIONS FULL-TEXT DATABASE, 1 May 2015 (2015-05-01), pages 1 - 140, XP055775976 * |
LI, Z. H. ET AL.: "Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity.", NAT COMMUN., vol. 9, no. 1, 18 December 2018 (2018-12-18), XP055776002, DOI: 10.1038/s41467-018-07199-6 * |
M. SHANK-RETZLAFFF. WANGT. MORLEY ET AL.: "Correlation between Mouse Potency and In Vitro Relative Potency for Human Papillomavirus Type 16 Virus-Like Particles and Gardasil Vaccine Samples", HUMAN VACCINES, vol. 1, no. 5, pages 191 - 197, XP055815561, DOI: 10.4161/hv.1.5.2126 |
MICHAEL J. CAULFIELDLI SHISU WANG ET AL.: "Effect of Alternative Aluminum Adjuvants on the Absorption and Immunogenicity of HPV16 L1 VLPs in Mice", HUMAN VACCINES, vol. 3, no. 4, pages 139 - 146 |
PIMIENTA ELSA, RODRÍGUEZ SANDRA, FANDO RAFAEL, SERRANO YUNIER, ORTEGA DARIÉN, PALENZUELA ARIEL, MARRERO KAREN: "Cloning and expression in Escherichia coli of the full-lengh and deletion variants of a human papillomavirus 18 L1 gene isolated from a Cuban patient", REVISTA CUBANA DE MEDICINA TROPICAL, vol. 71, no. 2, 1 January 2019 (2019-01-01), pages e301, XP055951381 * |
Also Published As
Publication number | Publication date |
---|---|
CA3204802A1 (en) | 2022-07-21 |
MX2023008306A (es) | 2023-07-19 |
EP4292607A1 (en) | 2023-12-20 |
CN117083078A (zh) | 2023-11-17 |
US20240075124A1 (en) | 2024-03-07 |
AU2022207569A1 (en) | 2023-08-10 |
KR20230129506A (ko) | 2023-09-08 |
JP2024503452A (ja) | 2024-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5956974B2 (ja) | パピローマウイルスワクチン組成物 | |
Stanley et al. | Immunobiology of human papillomavirus infection and vaccination-implications for second generation vaccines | |
WO2023116374A1 (zh) | 带状疱疹疫苗组合物 | |
US20210077611A1 (en) | Compositions, methods and uses for thermally stable human papillomavirus formulations | |
CN112043825A (zh) | 一种基于新型冠状病毒突刺蛋白s1区域预防新型冠状病毒感染的亚单位疫苗 | |
Su et al. | Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response | |
WO2016184425A1 (zh) | 截短的轮状病毒vp4蛋白及其用途 | |
JP2616915B2 (ja) | 中和糖タンパク質のペプチド | |
US20160000901A1 (en) | Compositions and Methods for the Production of Virus-Like Particles | |
Basu et al. | Bacteriophage Qβ virus-like particles displaying Chikungunya virus B-cell epitopes elicit high-titer E2 protein antibodies but fail to neutralize a Thailand strain of Chikungunya virus | |
JP4840774B2 (ja) | 経口投与ワクチン | |
Zhang et al. | A rationally designed flagellin-L2 fusion protein induced serum and mucosal neutralizing antibodies against multiple HPV types | |
US11858964B2 (en) | Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer | |
KR20110053340A (ko) | Hpv에 대한 백신 | |
WO2022152204A1 (zh) | 一种人***瘤病毒病毒样颗粒疫苗的稳定制剂 | |
WO2023001259A1 (zh) | 一种可诱导广谱中和活性重组多价新冠病毒三聚体蛋白疫苗的制备及应用 | |
WO2022100459A1 (zh) | 一种预防和治疗默克尔细胞癌的新型疫苗 | |
Yu et al. | A bacterially expressed triple-type chimeric vaccine against human papillomavirus types 51, 69, and 26 | |
WO2015068101A1 (en) | Papillomavirus vaccine formulations | |
US11273127B2 (en) | Compositions, methods and uses for thermally stable multi-targeted antigens | |
CN118059223A (zh) | 九价人***瘤病毒疫苗及其应用 | |
US20220372079A1 (en) | Resurfaced dengue virus and ziki virus glycoprotein e diii variants and uses thereof | |
US20210299238A1 (en) | Compositions, methods and uses for thermally stable broad-spectrum human papillomavirus formulations | |
WO2022068847A1 (zh) | 一种治疗或预防新型冠状病毒SARS-CoV-2引起的疾病的方法 | |
Morales | Using self-assembling peptides as a platform to create new human papillomavirus vaccine candidates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22739080 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280008056.4 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 3204802 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/008306 Country of ref document: MX Ref document number: 2023542604 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023014016 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20237026965 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020237026965 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2022207569 Country of ref document: AU Date of ref document: 20220113 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112023014016 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230712 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022739080 Country of ref document: EP Effective date: 20230814 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11202305338W Country of ref document: SG |